Our mission - is to facilitate the transition of the Russian pharmaceutical market to develop into mature, be a guide on the course of development of the potential of all the pharmaceutical market participants, thereby improving the quality of life for the end user and society in general. Despite the relatively high susceptibility to Russia's external economic and financial risks, imbalances in the domestic policy and great social disparities, the pharmaceutical market in Russia has had a stable positive growth for the last few years.
From 9 to 11 October in Voronezh, the 45th interregional specialized forum-exhibition "Healthcare" will be held - the largest exhibition and congress event in Voronezh in the field of healthcare, the largest in the region review of the achievements of scientific and practical medicine.
Approved the Administrative Regulations of the Ministry of Health of Russia on the provision of a public service for the accreditation of medical organizations for the right to conduct clinical trials of medicinal products for medical use. The corresponding order of the Ministry of Health of Russia on February 13, 1981 № 67n was registered by the Ministry of Justice on May 25.
The Federal Service for Supervision in Healthcare Informs about the adoption of the Resolution of the Government of the Russian Federation of 31.05.2018 No. 633 "On Amending the Rules for the State Registration of Medical Products".
The State Duma Committee for Health Protection supported by 18 votes in favor with two abstentions supported the concept of the bill "On measures of influence or counteraction to unfriendly actions of the United States and other foreign states", which provides, among other things, the possibility of banning the importation into Russia of American medicines for which there are analogues in the market.
The national projects of 2018-2024, over which the new government of Dmitry Medvedev will work, are very similar to the national projects of the times of his presidency in 2008-2012. In the "twenty-five-trillionth plan" of the White House, which Kommersant was familiar with, there are 13 projects that are already developing. His largest expenses are oncology program, providing the public sector and schools with digital communication channels, repairing roads in non-capital megacities and investing in Russian software for the "digital state".
Where in the conditions of deficit of budgets to take money for health care? This issue today became one of the main issues at the SPIEF session devoted to the increase in the life expectancy of Russians. The answer was formulated by the member of the State Duma Committee on Budget and Taxes, Airat Farrakhov. The expert stressed that the allocations to be allocated to the industry before 2024 will solve the key health problems of the Russian Federation. But not only the overall growth of health care financing is important until 2024, but the current increase in the financing of the health protection system is also important. First of all, the program of state guarantees, its basic part.
The process of including the drug in the VED list and registering its price is similar to the process of determining the price of medicines in other countries. About this "FV" on the sidelines of the Russian pharmaceutical forum in St. Petersburg, the general director of Merck Biopharma in Russia, Matthias Wernicke.
With the help of the Pharma-2020 program, it is planned to create a venture fund that will support the development of Russian pharmaceutical companies in the early stages, said Alexei Alekhin, head of the department for the development of pharmaceutical and medical industry of the Ministry of Industry and Trade at the St. Petersburg Economic Forum-2018.